Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Long-Term Investments (2022 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Long-Term Investments for 4 consecutive years, with $107.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 1.6% to $107.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.1 million through Dec 2025, down 1.6% year-over-year, with the annual reading at $107.1 million for FY2025, 1.6% down from the prior year.
  • Long-Term Investments hit $107.1 million in Q4 2025 for Harmony Biosciences Holdings, up from $105.8 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $108.9 million in Q4 2024 to a low of $4.7 million in Q2 2022.
  • Historically, Long-Term Investments has averaged $71.8 million across 4 years, with a median of $81.2 million in 2024.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 1135.54% in 2023 and later dropped 1.6% in 2025.
  • Year by year, Long-Term Investments stood at $22.6 million in 2022, then skyrocketed by 219.78% to $72.2 million in 2023, then soared by 50.86% to $108.9 million in 2024, then dropped by 1.6% to $107.1 million in 2025.
  • Business Quant data shows Long-Term Investments for HRMY at $107.1 million in Q4 2025, $105.8 million in Q3 2025, and $107.0 million in Q2 2025.